 | • レポートコード：360iR22DE108 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に122.9億ドルであった世界のコンパニオンアニマル用医薬品市場規模が、2022年に134.5億ドルになり、2027年まで年平均12.25％で成長して213.0億ドルに達すると予測しています。本レポートでは、コンパニオンアニマル用医薬品の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（行動障害、皮膚疾患、感染症、整形外科疾患、疼痛）分析、動物種類別（猫、犬、馬）分析、流通チャネル別（小売薬局、動物クリニック、動物病院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。本書では、Ashish Life Science Pvt. Ltd.、Boehringer Ingelheim International GmbH、Ceva Santé Animale、Chanelle Pharma、Dechra Pharmaceuticals PLC、Eco Animal Health Group PLC、Elanco Animal Health Incorporated、Endovac Animal Health, LLC、Hipra Laboratories, S.A.、Indian Immunologicals Ltd.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のコンパニオンアニマル用医薬品市場規模：疾患別 - 行動障害における市場規模 - 皮膚疾患における市場規模 - 感染症における市場規模 - 整形外科疾患における市場規模 - 疼痛における市場規模 ・世界のコンパニオンアニマル用医薬品市場規模：動物種類別 - 猫における市場規模 - 犬における市場規模 - 馬における市場規模 ・世界のコンパニオンアニマル用医薬品市場規模：流通チャネル別 - 小売薬局チャネルの市場規模 - 動物クリニックチャネルの市場規模 - 動物病院チャネルの市場規模 ・世界のコンパニオンアニマル用医薬品市場規模：地域別 - 南北アメリカのコンパニオンアニマル用医薬品市場規模 アメリカのコンパニオンアニマル用医薬品市場規模 カナダのコンパニオンアニマル用医薬品市場規模 ブラジルのコンパニオンアニマル用医薬品市場規模 ... - アジア太平洋のコンパニオンアニマル用医薬品市場規模 日本のコンパニオンアニマル用医薬品市場規模 中国のコンパニオンアニマル用医薬品市場規模 インドのコンパニオンアニマル用医薬品市場規模 韓国のコンパニオンアニマル用医薬品市場規模 台湾のコンパニオンアニマル用医薬品市場規模 ... -ヨーロッパ/中東/アフリカのコンパニオンアニマル用医薬品市場規模 イギリスのコンパニオンアニマル用医薬品市場規模 ドイツのコンパニオンアニマル用医薬品市場規模 フランスのコンパニオンアニマル用医薬品市場規模 ロシアのコンパニオンアニマル用医薬品市場規模 ... -その他地域のコンパニオンアニマル用医薬品市場規模 ・競争状況 ・企業情報 |
The Global Companion Animal Pharmaceuticals Market size was estimated at USD 12.29 billion in 2021 and expected to reach USD 13.45 billion in 2022, and is projected to grow at a CAGR 9.59% to reach USD 21.30 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Companion Animal Pharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indication, the market was studied across Behavioral Disorders, Dermatologic Diseases, Infectious Diseases, Orthopedic Diseases, and Pain.
Based on Animal Type, the market was studied across Cats, Dogs, and Horses.
Based on Distribution Channel, the market was studied across Retail Pharmacies, Veterinary Clinics, and Veterinary Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Alabama, Alaska, California, Florida, Georgia, Illinois, New York, Ohio, Pennsylvania, South Carolina, Texas, and Virginia. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Companion Animal Pharmaceuticals market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Companion Animal Pharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Companion Animal Pharmaceuticals Market, including Ashish Life Science Pvt. Ltd., Boehringer Ingelheim International GmbH, Ceva Santé Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, Elanco Animal Health Incorporated, Endovac Animal Health, LLC, Hipra Laboratories, S.A., Indian Immunologicals Ltd., Inovet Group, Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Merck & Co. Inc., Norbrook Laboratories Ltd., Tianjin Ringpu Biotechnology Co., Ltd., Vetoquinol S.A., Virbac S.A., and Zoetis Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Companion Animal Pharmaceuticals Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Companion Animal Pharmaceuticals Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Animal Pharmaceuticals Market?
4. What is the competitive strategic window for opportunities in the Global Companion Animal Pharmaceuticals Market?
5. What are the technology trends and regulatory frameworks in the Global Companion Animal Pharmaceuticals Market?
6. What is the market share of the leading vendors in the Global Companion Animal Pharmaceuticals Market?
7. What modes and strategic moves are considered suitable for entering the Global Companion Animal Pharmaceuticals Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Zoonotic and Chronic Diseases
5.1.1.2. Rising Number of Companion Animals and Awareness About their Hygiene
5.1.1.3. Increasing Awareness and Expenditure Among People Regarding Animal Healthcare
5.1.2. Restraints
5.1.2.1. Several Risk Factors Associated with Companion Animal Health APIs
5.1.3. Opportunities
5.1.3.1. Development of New Drugs and Vaccines for Companion Animal
5.1.3.2. Strategic Collaborations Along with Emergence of Market Players Across the Developing Economies
5.1.4. Challenges
5.1.4.1. Stringent Regulations Associated with the Approval for Drugs
5.2. Cumulative Impact of COVID-19
6. Companion Animal Pharmaceuticals Market, by Indication
6.1. Introduction
6.2. Behavioral Disorders
6.3. Dermatologic Diseases
6.4. Infectious Diseases
6.5. Orthopedic Diseases
6.6. Pain
7. Companion Animal Pharmaceuticals Market, by Animal Type
7.1. Introduction
7.2. Cats
7.3. Dogs
7.4. Horses
8. Companion Animal Pharmaceuticals Market, by Distribution Channel
8.1. Introduction
8.2. Retail Pharmacies
8.3. Veterinary Clinics
8.4. Veterinary Hospitals
9. Americas Companion Animal Pharmaceuticals Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Companion Animal Pharmaceuticals Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Companion Animal Pharmaceuticals Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Ashish Life Science Pvt. Ltd.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Boehringer Ingelheim International GmbH
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Ceva Santé Animale
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Chanelle Pharma
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Dechra Pharmaceuticals PLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Eco Animal Health Group PLC
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Elanco Animal Health Incorporated
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Endovac Animal Health, LLC
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Hipra Laboratories, S.A.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Indian Immunologicals Ltd.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Inovet Group
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Kyoritsu Seiyaku Corporation
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Lutim Pharma Pvt. Ltd.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Merck & Co. Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Norbrook Laboratories Ltd.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Tianjin Ringpu Biotechnology Co., Ltd.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Vetoquinol S.A.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Virbac S.A.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Zoetis Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing